BEd LLB - RepliCel Life Corp Director
| REPCF Stock | USD 0 0 950.00% |
Insider
BEd LLB is Corp Director of RepliCel Life Sciences
| Age | 56 |
| Phone | 604 248 8730 |
| Web | https://www.replicel.com |
RepliCel Life Management Efficiency
The company has return on total asset (ROA) of (1.651) % which means that it has lost $1.651 on every $100 spent on assets. This is way below average. RepliCel Life's management efficiency ratios could be used to measure how well RepliCel Life manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Andrew Cole | Vertiv Holdings Co | 54 | |
| Noha Abdalla | Choice Hotels International | 46 | |
| Matthew Louie | Vertiv Holdings Co | 42 | |
| Joshua Isner | Axon Enterprise | 38 | |
| Steven Reinemund | Vertiv Holdings Co | 72 | |
| Robert Zhu | Vertiv Holdings Co | 57 | |
| Michelle Daly | Nasdaq Inc | 47 | |
| Brittany Bagley | Axon Enterprise | 41 | |
| Robin Washington | Vertiv Holdings Co | 58 | |
| Steve Lalla | Vertiv Holdings Co | 57 | |
| Patrick Smith | Axon Enterprise | 53 | |
| Prof Dally | NVIDIA | 63 | |
| Jason Forcier | Vertiv Holdings Co | 48 | |
| Frank Shaw | Microsoft | N/A | |
| Luke Larson | Axon Enterprise | 43 | |
| Brian MBA | Choice Hotels International | N/A | |
| Jim Zito | Axon Enterprise | 43 | |
| Stephanie Gill | Vertiv Holdings Co | 49 | |
| Stephen Liang | Vertiv Holdings Co | 65 | |
| Erin Dowd | Vertiv Holdings Co | 53 | |
| Emily Spurling | Nasdaq Inc | N/A | |
Management Performance
| Return On Asset | -1.65 |
RepliCel Life Sciences Leadership Team
Elected by the shareholders, the RepliCel Life's board of directors comprises two types of representatives: RepliCel Life inside directors who are chosen from within the company, and outside directors, selected externally and held independent of RepliCel. The board's role is to monitor RepliCel Life's management team and ensure that shareholders' interests are well served. RepliCel Life's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, RepliCel Life's outside directors are responsible for providing unbiased perspectives on the board's policies.
| BA CPA, Chief Officer | ||
| Kevin McElwee, Chief Scientific Officer | ||
| MSc PMP, Clinical Consultant | ||
| Ben Austring, Chief Mang | ||
| Andrew Schutte, CEO Pres | ||
| BEd LLB, Corp Director | ||
| Rolf MD, Chief Board |
RepliCel Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is RepliCel Life a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -1.65 | |||
| Operating Margin | (4.19) % | |||
| Current Valuation | 3.42 M | |||
| Shares Outstanding | 54.36 M | |||
| Shares Owned By Insiders | 68.42 % | |||
| Price To Earning | (1.00) X | |||
| Price To Sales | 8.35 X | |||
| Revenue | 353.74 K | |||
| Gross Profit | 353.74 K | |||
| EBITDA | (4.07 M) |
Currently Active Assets on Macroaxis
Other Information on Investing in RepliCel Pink Sheet
RepliCel Life financial ratios help investors to determine whether RepliCel Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in RepliCel with respect to the benefits of owning RepliCel Life security.